Yahoo Web Search

Search results

1. • • The market seemed willing to give Baxter the benefit of the doubt at first, but a subsequent $3.1 billion impairment charge related to the acquisition confirmed our suspicions; the deal was a massive overpay. Baxter International Investor Relations Not only was the acquisition an overpay, it was an ill-timed one.
     seekingalpha.com/article/4726620-baxter-is-a-strong-buy-the-turnaround-story-you-cant-ignore

     Baxter Is A Strong Buy: The Turnaround Story You Can't Ignore

2. People also ask

   Was Baxter a massive overpay?

   • The market seemed willing to give Baxter the benefit of the doubt at first, but a subsequent $3.1 billion impairment charge related to the acquisition confirmed our suspicions; the deal was a massive overpay. Not only was the acquisition an overpay, it was an ill-timed one.

   Baxter Is A Strong Buy: The Turnaround Story You Can't Ignore

   seekingalpha.com/article/4726620-baxter-is-a-strong-buy-the-turnaround-story-you-cant-ignore

   See all results for this question

   How much does Baxter expect to make a year?

   • Baxter now expects full-year adjusted profit between $2.93 and $3.01 per share, compared with its previous view of $2.88 to $2.98 per share. Analysts estimated $2.92 per share, according to LSEG data. Revenue for the second-quarter ended June 30 came in at $3.81 billion, beating estimates of $3.76 billion.

   Baxter raises full-year profit forecast on robust demand for medical

   www.reuters.com/business/healthcare-pharmaceuticals/baxter-raises-full-year-profit-forecast-robust-demand-medical-devices-2024-08-06/

   See all results for this question

   Why is Baxter getting a lower price?

   • Baxter is set to receive less for the kidney care business than it was able to fetch last year for its much smaller biopharma solutions unit. The private equity firms Advent International and Warburg Pincus paid $4.25 billion for biopharma solutions. Slowing sales might be the reason for the lower price for the kidney care business.

   Private Equity Buys Another Piece of Baxter as Carlyle Scoops Up Kidney

   medcitynews.com/2024/08/baxter-carlyle-group-kidney-care-acquisition-private-equity-bax-cg/

   See all results for this question

   How has Baxter changed from a few years ago?

   • Baxter today looks remarkably different from just a few years ago. Thankfully, management simplified its structure from ten reporting segments to three following the kidney business sale: Medical Products & Therapies ($5 billion in FY2023), Healthcare Systems & Technologies ($3 billion in FY2023), and Pharmaceuticals ($2.3 billion in FY2023).

   Baxter Is A Strong Buy: The Turnaround Story You Can't Ignore

   seekingalpha.com/article/4726620-baxter-is-a-strong-buy-the-turnaround-story-you-cant-ignore

   See all results for this question

   Will Baxter pay off debt?

   • Baxter is expected to receive roughly $3 billion in net after-tax proceeds and use all of it to pay down debt. This will allow Baxter to pay off some of its most expensive debt, including a $1.6 billion term loan with a 6.5% interest rate due in 2026.

   Baxter Is A Strong Buy: The Turnaround Story You Can't Ignore

   seekingalpha.com/article/4726620-baxter-is-a-strong-buy-the-turnaround-story-you-cant-ignore

   See all results for this question

   Why did Baxter pay a lower price for kidney care?

   • The private equity firms Advent International and Warburg Pincus paid $4.25 billion for biopharma solutions. Slowing sales might be the reason for the lower price for the kidney care business. Kidney care is currently one of four Baxter operating segments.

   Private Equity Buys Another Piece of Baxter as Carlyle Scoops Up Kidney

   medcitynews.com/2024/08/baxter-carlyle-group-kidney-care-acquisition-private-equity-bax-cg/

   See all results for this question

3. medcitynews.com › 2024 › 08Private Equity Buys Another Piece of Baxter as Carlyle Scoops ...

   medcitynews.com › 2024 › 08

   • Cached

   Aug 13, 2024 · By Stephanie Baum. Baxter is set to receive less for the kidney care business than it was able to fetch last year for its much smaller biopharma solutions unit. The private equity firms Advent...

4. www.chicagobusiness.com › health-pulse › baxterBaxter overpaid for Hillrom • Sale of Weiss Memorial, West ...

   www.chicagobusiness.com › health-pulse › baxter

   • Cached

   Nov 28, 2022 · FILING CONFIRMS BAXTER OVERPAID FOR HILLROM: Baxter International flubbed its biggest acquisition ever, tanking its stock price while raising doubts about CEO José Almeida's growth strategy...

5. investor.baxter.com › investors › events-and-newsBaxter Reports Fourth-Quarter and Full-Year 2023 Results

   investor.baxter.com › investors › events-and-news

   • Cached

   Feb 8, 2024 · Fourth-quarter sales from continuing operations of $3.89 billion increased 4% on a reported basis and 3% on a constant currency basis 1 Fourth-quarter U.S. GAAP diluted earnings per share (EPS) from continuing operations of $0.14 and adjusted diluted EPS from continuing operations of $0.88 Full-year sales from continuing operations of $14.81 ...

6. www.chicagobusiness.com › health-care › baxterBaxter reports $2.8 billion impairment charge on Hillrom ...

   www.chicagobusiness.com › health-care › baxter

   • Cached

   Oct 28, 2022 · Baxter International, the Deerfield-based medical device company, revealed in its third-quarter earnings that it took a nearly $3 billion impairment charge related to its $10.5 billion Hillrom...

7. www.chicagobusiness.com › health-care › baxter-stockBaxter stock drops after Hillrom buyout | Crain's Chicago ...

   www.chicagobusiness.com › health-care › baxter-stock

   • Cached

   Nov 28, 2022 · Shares tumbled after a massive write-down showed the medical products manufacturer overpaid for Hillrom. Now Baxter could be a target for a takeover.

8. www.reuters.com › business › healthcareBaxter raises full-year profit forecast on robust demand for ...

   www.reuters.com › business › healthcare

   Aug 6, 2024 · Baxter now expects full-year adjusted profit between $2.93 and $3.01 per share, compared with its previous view of $2.88 to $2.98 per share. Analysts estimated $2.92 per share, according to...